Evidence map›Paper›PMID 36749446›Full record

ArticleEJNMMI physics2023

Dosimetric impact of 3D motion-compensated SPECT reconstruction for SIRT planning.

Laure Vergnaud, Antoine Robert, Thomas Baudier, Sandrine Parisse-Di Martino, Philippe Boissard, Simon Rit, Jean-Noël Badel, David Sarrut

Open access · goldAbstract read
In one paragraph

Article in EJNMMI physics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
1.1field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Laure VergnaudCREATIS; CNRS UMR 5220; INSERM U 1044; Université de Lyon; INSA-Lyon, Université Lyon 1, Lyon, France. Laure.Vergnaud@creatis.insa-lyon.fr.ORCID http://orcid.org/0000-0003-3813-6467
Antoine RobertCREATIS; CNRS UMR 5220; INSERM U 1044; Université de Lyon; INSA-Lyon, Université Lyon 1, Lyon, France.
Thomas BaudierCREATIS; CNRS UMR 5220; INSERM U 1044; Université de Lyon; INSA-Lyon, Université Lyon 1, Lyon, France.
Sandrine Parisse-Di MartinoCentre de Lutte Contre Le Cancer Léon Bérard, Lyon, France.
Philippe BoissardCentre de Lutte Contre Le Cancer Léon Bérard, Lyon, France.
Simon RitCREATIS; CNRS UMR 5220; INSERM U 1044; Université de Lyon; INSA-Lyon, Université Lyon 1, Lyon, France.
Jean-Noël BadelCentre de Lutte Contre Le Cancer Léon Bérard, Lyon, France.
David SarrutCREATIS; CNRS UMR 5220; INSERM U 1044; Université de Lyon; INSA-Lyon, Université Lyon 1, Lyon, France.
Université Claude Bernard Lyon 1 · FRCentre Léon Bérard · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn selective internal radiation therapy,

methodsTwenty-nine patients with liver cancer or hepatic metastases treated by radioembolization were included in this study. The biodistribution of

resultsThe mean amplitude of the liver was 9.5 ± 2.7 mm. Medians of PDD were closed to zero for all VOI except for lungs (6.4%) which means that the motion compensation overestimates the absorbed dose to the lungs compared to the 3D reconstruction. The smallest lesions had higher PDD than the largest ones. Between 3D and 3Dcomp reconstructions, means of differences in lung dose and TN ratio were not statistically significant, but in some cases these differences exceed 1 Gy (4/31) and 8% (2/31). The absolute differences in activity were on average 3.1% ± 5.1% and can reach 22.8%.

conclusionThe correction of respiratory motion mainly impacts the lung and tumor doses but only for some patients. The largest dose differences are observed for the smallest lesions.

Indexed as

3D compensated reconstruction99mTc-MAABreathing motionDosimetryRadioembolizationSPECT/CT

Identifiers

PMID36749446
PMCPMC9905464
OpenAlexW4319333947

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.